Publication of the LOCATION Clinical Study Results in the Renowned Scientific Journal of the European Atherosclerosis Society (EAS)

Cerenis Therapeutics (Paris:CEREN) (FR0012616852 - CEREN), an international biopharmaceutical company dedicated to the discovery and development of innovative HDL therapies ("good cholesterol”) for treating cardiovascular and metabolic diseases, today announces the publication of the LOCATION clinical study results in the internationally peer-reviewed journal ATHEROSCLEROSIS (Click here to access the abstract), the reference publication of the European Atherosclerosis Society (EAS).

Dr. Jean-Louis Dasseux, Founder and CEO of Cerenis Therapeutics declared: "Results of the LOCATION study offer a valuable validation of the functionality of CER-001, demonstrating the mimetic’s capacity to penetrate the vessel walls, to preferentially target atherosclerotic plaques and to increase cholesterol efflux capacity. Indeed, these outcomes are of major scientific importance, as proved by their publication in the world-renowned scientific journal ATHEROSCLEROSIS. Additionally, they are particularly reassuring prior to the publication of the CARAT study results, planned for first quarter of 2017, as the targeting of atherosclerotic plaques was observed at the dose of 3 mg/kg, dose used in this phase II clinical study in post-ACS patients which intends to demonstrate plaque regression”.

Professor Erik Stroes, Principal Investigator of the LOCATION study commented: " The LOCATION study confirms for the first time the targeting of atherosclerotic plaques by apoA-I containing HDL mimetics in humans, an effect only previously observed in experimental models of atherosclerotic disease. Our results are also consistent with the observed reduction in atherosclerosis shown in patients with HDL deficiencies, in patients with homozygous familial hypercholesterolaemia, and in post-ACS patients. Our data support the concept that CER-001 targets plaque regions in patients, which correlates with plaque contrast enhancement. These clinical findings are supportive of the ongoing CARAT and TANGO studies and may also guide future nanomedicine development using HDL particles for drug delivery in atherosclerosis”.

To read the complete press release, please visit Cerenis’ corporate website

About Cerenis Therapeutics: www.cerenis.com
Cerenis Therapeutics is an international biopharmaceutical company dedicated to the discovery and development of innovative HDL therapies for the treatment of cardiovascular and metabolic diseases. HDL is the primary mediator of the reverse lipid transport, or RLT, the only natural pathway by which excess cholesterol is removed from arteries and is transported to the liver for elimination from the body.

Cerenis is developing a portfolio of HDL therapies, including HDL mimetics for the rapid regression of atherosclerotic plaque in high-risk patients such as post-ACS patients and patients with HDL deficiency, and drugs which increase HDL for patients with low number of HDL particles to treat atherosclerosis and associated metabolic diseases.

Cerenis is well positioned to become one of the leaders in the HDL therapeutic market, with a broad portfolio of programs being developed.

Since its inception in 2005, the company has been funded by top tier investors: Sofinnova Partners, HealthCap, Alta Partners, EDF Ventures, Daiwa Corporate Investment, TVM Capital, Orbimed, IRDI/IXO Private Equity and Bpifrance (Fund for Strategic Investment) and last March successfully completed an IPO on Euronext raising €53.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160602005593/en/